

- [0874] Stiasny-Kolster et al., "The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument," *Movement disorders: Official J. of the Movement Dis. Soc.*, 22:2386-93 (2007).
- [0875] Stolzenberg et al., "A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity," *J. Innate Immun.*, 9:456-63 (2017).
- [0876] Svensson et al., "Does vagotomy reduce the risk of Parkinson's disease: The authors reply" *Ann. Neurol.*, 78:1012-3 (2015).
- [0877] Tang et al., "Loss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits," *Neuron*, 83(5):1131-1143 (2014).
- [0878] Videnovic A, Golombek D., "Circadian Dysregulation in Parkinson's Disease," *Neurobiol. Sleep Circadian Rhythms*, 2:53-8 (2017).
- [0879] West et al., "Squalamine increases vagal afferent firing frequency in aging mice," *J. of the Canadian Association of Gastroenterology*, 1 (2018).
- [0880] Wimo et al., "The worldwide economic impact of dementia 2010," *Alzheimer's Dement.*, 9: 1-11 (2013).
- [0881] Zahodne et al., "Mood and motor trajectories in Parkinson's disease: multivariate latent growth curve modeling," *Neuropsychology*, 26:71-80 (2012).
- [0882] Zinsmeister et al., "Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations," *Dig. Dis. Sci.*, 58:509-18 (2013).
- [0883] Learning About Parkinson's Disease, NIH Nat'l Human Genome Research Inst., <https://www.genome.gov/10001217/learning-about-parkinsons-disease/> (last updated Mar. 14, 2014); Parkinson Disease, NIH U.S. Nat'l Library of Med.: Genetics Home Reference, <https://ghr.nlm.nih.gov/condition/parkinson-disease#genes> (last updated Jul. 3, 2018).

1. A method of treating, preventing, and/or slowing the onset or progression in a subject in need of a condition selected from the group consisting of Parkinson's disease (PD) and/or a related symptom, autism spectrum disorder (ASD) and/or a related symptom, Alzheimer's disease (AD) and/or a related symptom, depression and/or a related symptom, or constipation and/or a related symptom,

wherein the method comprises administering to the subject a therapeutically effective amount of at least one aminosterol, or a salt or derivative thereof, provided that the method of administering does not comprise oral administration.

2. A method of treating, preventing, and/or slowing the onset or progression in a subject in need of a condition selected from the group consisting of schizophrenia and/or a related symptom, erectile dysfunction and/or a related symptom, high blood pressure (HBP) and/or a related condition, low blood pressure (LBP) and/or a related condition, multiple system atrophy and/or a related symptom, Cardiac Conduction Defects and/or a related symptom

wherein the method comprises administering to the subject a therapeutically effective amount of at least one aminosterol, or a salt or derivative thereof.

3. The method of claim 2, wherein the method of administration comprises oral, nasal, sublingual, buccal, rectal, vaginal, intravenous, intra-arterial, intradermal, intraperitoneal, intrathecal, intramuscular, epidural, intracerebral, intracerebroventricular, transdermal, or any combination thereof.

4. The method of claim 1, wherein the therapeutically effective amount of at least one aminosterol, or a salt or derivative thereof:

- (a) comprises about 0.1 to about 20 mg/kg body weight of the subject; and/or
- (b) comprises about 0.1 to about 15 mg/kg body weight of the subject; and/or
- (c) comprises about 0.1 to about 10 mg/kg body weight of the subject; and/or
- (d) comprises about 0.1 to about 5 mg/kg body weight of the subject; and/or
- (e) comprises about 0.1 to about 2.5 mg/kg body weight of the subject; and/or
- (f) comprises about 0.001 to about 500 mg/day; and/or
- (g) comprises about 0.001 to about 250 mg/day; and/or
- (h) comprises about 0.001 to about 125 mg/day; and/or
- (i) comprises about 0.001 to about 50 mg/day; and/or
- (j) comprises about 0.001 to about 25 mg/day; and/or
- (k) comprises about 0.001 to about 10 mg/day; and/or
- (l) comprises about 0.001 to about 6 mg/day administered intranasal; and/or
- (m) comprises about 0.001 to about 4 mg/day administered intranasal; and/or
- (n) comprises about 0.001 to about 2 mg/day administered intranasal; and/or
- (o) comprises about 0.001 to about 1 mg/day administered intranasal; and/or
- (p) comprises about 1 to about 300 mg/day administered orally; and/or
- (q) comprises about 25 to about 300 mg/day administered orally.

5. A method of treating a subject in need, wherein the subject has a condition amenable to treatment and/or prevention and/or amelioration with an aminosterol, comprising determining a dose of an aminosterol or a salt or derivative thereof for the subject, wherein the aminosterol dose is determined based on the effectiveness of the aminosterol dose in improving or resolving a symptom being evaluated, wherein the symptom is related to the condition, followed by administering the aminosterol dose to the subject for a period of time, wherein the method comprises:

- (a) identifying a symptom to be evaluated;
- (b) identifying a starting aminosterol dose for the subject;
- (c) administering an escalating dose of the aminosterol to the subject over a period of time until an effective dose for the symptom being evaluated is identified, wherein the effective dose is the dose where improvement or resolution of the symptom is observed, and fixing the aminosterol dose at that level for that particular symptom in that particular subject; and
- (d) optionally wherein each defined period of time is independently selected from the group consisting of about 1 day to about 10 days, about 10 days to about 30 days, about 30 days to about 3 months, about 3 months to about 6 months, about 6 months to about 12 months, and about greater than 12 months.

6. The method of claim 5, wherein the aminosterol or a salt or derivative thereof is administered orally, intranasally, or a combination thereof.

7. The method of claim 5, wherein:

- (a) the aminosterol or a salt or derivative thereof is administered orally and the starting dose of the aminosterol or a salt or derivative thereof ranges from about 1 mg up to about 175 mg/day; and/or